药学学报, 2021, 56(2): 511-519
引用本文:
李依宁, 韩小婉, 王伟志, 姜新海, 韩江雪, 张晶, 李霓, 李东升, 盛任, 巫晔翔, 徐扬, 任羽, 许艳妮, 司书毅. 吴茱萸次碱抗骨质疏松作用研究[J]. 药学学报, 2021, 56(2): 511-519.
LI Yi-ning, HAN Xiao-wan, WANG Wei-zhi, JIANG Xin-hai, HAN Jiang-xue, ZHANG Jing, LI Ni, LI Dong-sheng, SHENG Ren, WU Ye-xiang, XU Yang, REN Yu, XU Yan-ni, SI Shu-yi. Rutaecarpine exerted anti-osteroporosis[J]. Acta Pharmaceutica Sinica, 2021, 56(2): 511-519.

吴茱萸次碱抗骨质疏松作用研究
李依宁1, 韩小婉1,2, 王伟志1, 姜新海1, 韩江雪1, 张晶1, 李霓1,2, 李东升1, 盛任1, 巫晔翔1, 徐扬1, 任羽1, 许艳妮1, 司书毅1
1. 中国医学科学院、北京协和医学院医药生物技术研究所, 国家新药 (微生物) 筛选中心, 卫健委抗生素生物工程重点实验室, 北京 100050;
2. 中国医学科学院、北京协和医学院药物研究所, 北京 100050
摘要:
骨保护素(osteoprotegerin,OPG)是骨转换的标志物,由成骨细胞等分泌。OPG与核因子-κB受体活化因子配体(receptor activator of nuclear factor-κB ligand,RANKL)结合发挥抑制破骨细胞作用。本研究发现吴茱萸次碱(rutaecarpine,RUT)具有上调OPG表达的活性,并能显著增加小鼠胚胎成骨前体细胞MC3T3-E1及人骨肉瘤细胞U-2OS中OPG的蛋白水平。钙化结节染色实验结果表明,RUT显著促进MC3T3-E1细胞向成骨细胞分化;抗酒石酸磷酸酶(tartrate resistant acid phosphatase,TRAP)染色结果表明,RUT显著抑制RANKL诱导的小鼠巨噬细胞RAW264.7向破骨分化。体内研究发现,与卵巢去势(ovariectomized,OVX)大鼠模型组相比,RUT低剂量组(5 mg·kg-1·day-1)和高剂量组(45 mg·kg-1·day-1)灌胃给药3个月,显著增加OVX大鼠骨密度;钙黄绿素双标实验及甲苯胺蓝染色实验结果表明,RUT低剂量组在体内促进骨形成并减少骨量丢失;免疫组化结果显示RUT低剂量组能够增加大鼠股骨中OPG的表达。动物福利和实验过程均遵循中国医学科学院医药生物技术研究所动物伦理委员会的规定。综上,本研究表明RUT能上调OPG表达并在体内外促进成骨分化和抑制破骨分化。
关键词:    骨质疏松      吴茱萸次碱      骨保护素      成骨分化      破骨分化      卵巢去势大鼠     
Rutaecarpine exerted anti-osteroporosis
LI Yi-ning1, HAN Xiao-wan1,2, WANG Wei-zhi1, JIANG Xin-hai1, HAN Jiang-xue1, ZHANG Jing1, LI Ni1,2, LI Dong-sheng1, SHENG Ren1, WU Ye-xiang1, XU Yang1, REN Yu1, XU Yan-ni1, SI Shu-yi1
1. NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Osteoprotegerin (OPG), secreted by osteoblasts, is a marker of bone turnover. OPG can inhibit osteoclastic differentiation by binding receptor activator of nuclear factor-κB ligand (RANKL). In this study, we found that rutaecarpine (RUT) had the up-regulating OPG activity, and it could significantly increase OPG protein levels in both mouse embryonic osteogenic precursor MC3T3-E1 and human osteosarcoma U-2OS cells. Osteoblastogenic differentiation calcified nodules staining results showed that RUT significantly promoted the osteogenic differentiation of MC3T3-E1 cells. Osteoclastic differentiation tartrate resistant acid phosphatase (TRAP) staining results showed that RUT obviously inhibited the osteoclast differentiation of mouse macrophages RAW264.7 induced by RANKL. In vivo studies showed that low-dose RUT group (5 mg·kg-1·day-1) and high-dose RUT group (45 mg·kg-1·day-1) treatments for 3 months significantly increased bone density in ovariectomized (OVX) rats; calcein double labeling experiment and toluidine blue staining results indicated that low-dose RUT group promoted bone formation and decreased bone loss in vivo; immunohistochemistry results showed that low-dose RUT group increased the expression of OPG in rat femur. All animal procedures were performed in accordance with the regulations of the Institutional Animal Care and Use Committee of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. In summary, this study demonstrated that RUT could up-regulate OPG expression and had promoting osteoblastic differentiation and inhibiting osteoclastic differentiation effects in vitro and in vivo.
Key words:    osteoporosis    rutaecarpine    osteoprotegerin    osteogenic differentiation    osteoclastic differentiation    ovariectomized rat   
收稿日期: 2020-10-16
DOI: 10.16438/j.0513-4870.2020-1616
基金项目: 国家重大新药创制专项(2018ZX09711001-003-006);中国医学科学院医学与健康科技创新工程专项经费(2016-I2M-1-011);中国医学科学院医学与健康科技创新工程健康长寿先导科技专项(2019-RC-HL-009);国家自然科学基金面上项目(81973328).
通讯作者: 许艳妮,Tel:86-10-63180623,E-mail:xuyanniwendeng@hotmail.com;司书毅,Tel/Fax:86-10-63180604,E-mail:sisyimb@hotmail.com
Email: xuyanniwendeng@hotmail.com;sisyimb@hotmail.com
相关功能
PDF(1275KB) Free
打印本文
0
作者相关文章
李依宁  在本刊中的所有文章
韩小婉  在本刊中的所有文章
王伟志  在本刊中的所有文章
姜新海  在本刊中的所有文章
韩江雪  在本刊中的所有文章
张晶  在本刊中的所有文章
李霓  在本刊中的所有文章
李东升  在本刊中的所有文章
盛任  在本刊中的所有文章
巫晔翔  在本刊中的所有文章
徐扬  在本刊中的所有文章
任羽  在本刊中的所有文章
许艳妮  在本刊中的所有文章
司书毅  在本刊中的所有文章

参考文献:
[1] Raisz LG. Pathogenesis of osteoporosis:concepts, conflicts, and prospects[J]. J Clin Invest, 2005, 115:3318-3325.
[2] Chen X, Wang Z, Duan N, et al. Osteoblast-osteoclast interactions[J]. Connect Tissue Res, 2018, 59:99-107.
[3] Coughlan T, Dockery F. Osteoporosis and fracture risk in older people[J]. Clin Med (Lond), 2014, 14:187-191.
[4] Ominsky MS, Stolina M, Li X, et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength[J]. J Bone Miner Res, 2009, 24:1234-1246.
[5] Ozaki Y, Koide M, Furuya Y, et al. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis[J]. PLoS One, 2017, 12:e0184904.
[6] Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89:309-319.
[7] Nagy V, Penninger JM. The RANKL-RANK story[J]. Gerontology, 2015, 61:534-542.
[8] Infante M, Fabi A, Cognetti F, et al. RANKL/RANK/OPG system beyond bone remodeling:involvement in breast cancer and clinical perspectives[J]. J Exp Clin Cancer Res, 2019, 38:12.
[9] Silva I, Branco JC. Rank/Rankl/opg:literature review[J]. Acta Reumatol Port, 2011, 36:209-218.
[10] Gong S, Han X, Li X, et al. Development of a high-throughput screening strategy for upregulators of the OPG/RANKL ratio with the potential for antiosteoporosis effects[J]. J Biomol Screen, 2016, 21:738-748.
[11] Ren H, Liang D, Shen G, et al. Effects of combined ovariectomy with dexamethasone on rat lumbar vertebrae[J]. Menopause, 2016, 23:441-450.
[12] Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin and its ligands in vascular function[J]. Int J Mol Sci, 2019, 20:705.
[13] Guo QP. Improvement of alizarin red stain method for osteoblasts[J]. Technol Life (科技与生活), 2012, 4:174.
[14] Trouvin AP, Goeb V. Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin:maintaining the balance to prevent bone loss[J]. Clin Interv Aging, 2010, 5:345-354.
[15] Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond[J]. Front Immunol, 2014, 5:511.
[16] Zhou ZH, Xiao JR. Regulation of Wnt/beta-catenin signaling in bone development and bone tumor[J]. Chin J Surg (中华外科杂志), 2018, 56:797-800.
[17] Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats[J]. J Bone Miner Res, 2010, 25:2412-2418.
[18] Han X, Gong S, Li N, et al. A novel small molecule which increases osteoprotegerin expression and protects against ovariectomy-related bone loss in rats[J]. Front Pharmacol, 2019, 10:103.
[19] Zhou N, Li Q, Lin X, et al. BMP2 induces chondrogenic differentiation, osteogenic differentiation and endochondral ossification in stem cells[J]. Cell Tissue Res, 2016, 366:101-111.
[20] Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation[J]. Histochem Cell Biol, 2018, 149:313-323.
相关文献:
1.韩小婉, 宫世强, 李雪虹, 贺晓波, 姜威, 司书毅.BMP2表达上调剂E40071体外抗骨质疏松活性研究[J]. 药学学报, 2016,51(3): 396-402